Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
25/11/2024 14:17
Nov 25 (Reuters) - IGC Pharma Inc IGC.A :
* IGC PHARMA ANNOUNCES ADDITIONAL PHASE 2 INTERIM RESULTS
HIGHLIGHTING COGNITIVE BENEFITS OF IGC-AD1 FOR ALZHEIMER'S
TREATMENT
* IGC PHARMA INC - NO SERIOUS ADVERSE EVENTS OR DEATHS
REPORTED IN
TRIAL
* IGC PHARMA INC - INTERIM RESULTS SHOW COGNITIVE
IMPROVEMENT IN
ACTIVE TREATMENT GROUP
Source text: ID:nBw5M9Lfqa
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment